A newly developed injectable drug that blocks HIV from entering cells potentially could provide patients with long-lasting protection from the infection with fewer side effects.
Scientists have developed an injectable drug that blocks HIV from entering cells. They say the new drug potentially offers long-lasting protection from the infection with fewer side effects. The drug, which was tested in non-human primates, could eventually replace or supplement components of combination drug “cocktail” therapies currently used to prevent or treat the virus.
University of Utah Health scientists led the study in collaboration with researchers from the National Institute of Allergy and Infectious Diseases (NIAID), Beth Israel Deaconess Medical Center in Boston, and Navigen, Inc.
“This is an exciting new HIV therapeutic option for both prevention and treatment, with a unique mechanism of action compared to other approved drugs,” says Michael S. Kay, M.D. Ph.D., a senior author of the study and a U of U Health professor of biochemistry. “It has great potential to help patients who suffer from drug resistance as well as those who would benefit from a longer-acting, injectable anti-HIV drug cocktail.”
The study appears in Proceedings of the National Academy of Sciences (PNAS).
In 2019, about 1.7 million people worldwide were newly infected with HIV, according to the World Health Organization. More than 38 million people are currently living with the infection. Combination antiretroviral therapy (cART), the so-called “drug cocktail,” has dramatically improved survival and quality of life for such patients, but it is also costly, often has serious side effects, and requires patients to take pills daily. In addition, because HIV frequently mutates, drug resistance is a constant challenge, Kay says, so researchers are always seeking new drugs with novel mechanisms of action to produce more robust combination therapies.
“This is an exciting new HIV therapeutic option for both prevention and treatment, with a unique mechanism of action.”
In this new study, the researchers tested a unique drug called CPT31, based on a D-peptide that targets a critical pocket on HIV’s fusion machinery that rarely mutates. D-peptides are mirror images of naturally occurring peptides. To imagine it, think of right and left hands. The building blocks and overall structure of natural peptides are analogous to our left hand versus our right hand for D-peptides.
Because of that, CPT31 and other D-peptides are not degraded in the body. Therefore, they last much longer than natural peptides, making them especially suitable for a long-acting injectable formulation.
“In addition to their durability in the body, D-peptides are largely ignored by the immune system, preventing immune reactions that are a side effect often seen with traditional peptide and protein drugs,” says Brett Welch, a co-author of the study and senior director of technology and strategy at Navigen, Inc., the Salt Lake City company that co-developed CPT31 and is managing clinical trials. “As a D-peptide, our hope is that CPT31 will provide extended viral suppression with a lower dose and reduced side effects.”
To see if CPT31 could prevent HIV infection, Kay and colleagues first injected the drug into healthy macaque monkeys starting several days prior to exposure to a hybrid simian-human form of HIV called SHIV. The monkeys were completely protected from this very high SHIV exposure, much higher than what humans typically encounter, and never developed signs of infection. Subsequently, the scientists identified the minimum dose of CPT31 needed to confer complete protection, information that will help inform clinical trials.
“We think this drug could be used by itself to prevent HIV infection because initial HIV exposure typically involves a relatively small amount of virus,” Kay says. “This study showed that the vast majority of circulating HIV strains from around the world are potently blocked by CPT31.”
But what about later stages of the disease when there are billions of copies of the virus circulating in the body?
To find out, the researchers gave CPT31 to monkeys with untreated SHIV infections and high viral loads. Over the course of 30 days, the drug significantly lowered the presence of SHIV in their bloodstreams. However, virus levels rebound in two to three weeks due to drug resistance, as typically observed when treating established infections with a single drug.
“Such a simplified ‘maintenance therapy’ could present patients with a new option for viral control that is more cost-effective, convenient to take, and has fewer side effects,” Kay says.
In parallel with clinical trials, Navigen is developing a long-acting injectable formulation of CPT31 with the goal of only requiring injection of the drug once every three months.
“Long-acting injectable formulations appear to be greatly preferred by both patients and physicians compared to current daily drug regimens that can be challenging to maintain,” Welch says. “Additionally, the steady therapeutic drug levels provided by such a formulation would reduce the risk of drug resistance caused by missed daily pills, as well as reduce side effects.”
Upcoming human trials, scheduled for later this year, will help determine whether CPT31 is safe and effective in humans. Kay says that the full course of human clinical trials and subsequent FDA approval could take several years.
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Injectable HIV drug
- At Least 3 Women Contracted HIV After Getting "Vampire Facial" At Spa, US Health Body Finds
Three women were likely infected with HIV while receiving a so-called vampire facial at a New Mexico spa, marking the first known cases of the virus being transmitted during a cosmetic injection ...
- CDC describes first known cases of HIV transmitted via 'vampire facial' injections
Three women likely got HIV while receiving “vampire facials” at a New Mexico spa — the first known cases transmitted via cosmetic injections, a CDC report says.
- At least three women were infected with HIV after ‘vampire facials’
It is the first time that HIV transmission through cosmetic injection services has been documented, officials said. The spa was not licensed for such services.
- Three women likely contracted HIV from 'vampire facials' at closed New Mexico Spa: CDC
HIV cases have been attributed to "vampire facials" three women received at an Albuquerque, New Mexico spa, the CDC says.
- CDC describes how unlicensed ‘vampire facial’ treatment infected women with HIV
Three women likely were infected with HIV after undergoing “vampire facials” at an unlicensed New Mexico spa, the first known instance of the virus being transmitted through cosmetic injection ...
Go deeper with Google Headlines on:
Injectable HIV drug
[google_news title=”” keyword=”injectable HIV drug” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
Prevention and treatment of HIV
- CDC releases report on first HIV cases 'likely' spread from vampire facials at ABQ spa
The Centers for Disease Control and Prevention says the first known cases of HIV reportedly spread through so-called vampire facials were tied to a spa in Northwest Albuquerque.
- 'We help people live and thrive': AVOL talks advances in HIV prevention and treatment ahead of AIDS walk
This weekend marks the 31st annual AVOL Lexington AIDS Walk in Lexington, a chance to remember those lost to the disease and to celebrate the advances being made in HIV prevention and treatment.
- CDC report sheds light on HIV cases linked to ‘vampire facials’ at former Albuquerque spa
The Centers for Disease Control and Prevention (CDC) released new information about an Albuquerque spa that was shut down by health regulators after clients were ...
- Cluster of HIV cases linked to microneedling treatments at New Mexico spa
A cluster of clients who had gotten "vampire facial" microneedling skin treatments at a New Mexico spa were diagnosed with HIV, probably via poorly cleaned instruments, a new report finds.
- CDC describes how unlicensed ‘vampire facial’ treatment infected women with HIV
Three women likely were infected with HIV after undergoing “vampire facials” at an unlicensed New Mexico spa, the first known instance of the virus being transmitted through cosmetic injection ...
Go deeper with Google Headlines on:
Prevention and treatment of HIV
[google_news title=”” keyword=”prevention and treatment of HIV” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]